{"slideshow_credits": null, "snippet": "The new study found there was no difference in the aortic growth rate between those taking losartan and those taking the standard treatment.", "abstract": "Three-year study published in The New England Journal of Medicine reveals that blood pressure drug found to block the effects of a gene mutation that causes Marfan syndrome, condition that leads to heart problems, is no more effective than standard treatment.", "section_name": "Health", "print_page": "14", "document_type": "article", "byline": {"person": [{"firstname": "Gina", "role": "reported", "lastname": "KOLATA", "rank": 1, "organization": ""}], "original": "By GINA KOLATA", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/11/19/health/study-tempers-promise-of-drug-for-marfan-syndrome.html", "lead_paragraph": "The new study found there was no difference in the aortic growth rate between those taking losartan and those taking the standard treatment.", "headline": {"main": "Heart Drug, Losartan, Falls Short of Promise in a Study", "print_headline": "Heart Drug Falls Short of Promise in a Study"}, "_id": "546b7d3538f0d869ced9a4d9", "word_count": "703", "multimedia": [], "pub_date": "2014-11-19T00:00:00Z", "source": "The New York Times", "news_desk": "National", "keywords": [{"name": "subject", "value": "Blood Pressure", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Marfan Syndrome", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Heart", "is_major": "Y", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "4"}, {"name": "organizations", "value": "New England Journal of Medicine", "is_major": "Y", "rank": "5"}, {"name": "subject", "value": "Placebos", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "News"}